News | April 25, 2013

Toshiba Partners With Leading Universities for Advanced MR Research

Introduces new sequence development environment at ISMRM

April 25, 2013 — Leading research institutions are making breakthroughs in advanced magnetic resonance (MR) imaging with Toshiba America Medical Systems Inc.’s Vantage Titan 3.0T MR system. Toshiba has partnered with Shands at the University of Florida and the Keck Medical Center of the University of Southern California (USC) for MR clinical research in functional MRI (fMRI), as well as body and cardiac imaging.

 “We’re utilizing the Titan 3.0T MR to enhance visualization of cerebral spinal fluid (CSF) flow non-invasively and in the research of traumatic brain injuries from combat and athletics,” said Anthony Mancuso, professor and chairman of the department of radiology, UF College of Medicine. “The Titan 3.0T fulfills all the promises of a high-end 3.0T system, with high image quality, gradient homogeneity and patient-focused features.”

As part of Toshiba’s commitment to supporting institutions in advanced MR research, Toshiba is demonstrating the new sequence development environment (NSDE), a research-only tool that allows the research community to develop its own pulse sequences to explore new applications of MR imaging.

“Partnering with prestigious universities such as USC and Shands at the University of Florida illustrates our commitment to developing advanced technology that can expand the potential clinical applications of MR imaging,” said Suresh Narayan, senior manager, market development, MR business unit, Toshiba.

Toshiba showcased the Titan 3.0T with NSDE at this year’s International Society for Magnetic Resonance in Medicine (ISMRM) annual meeting in Salt Lake City, April 20-26, 2013.

For more information: www.medical.toshiba.com


Related Content

News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
Subscribe Now